Diabetes

Rx products features in the April 2020 issue.

New research has found that hospitalized patients with COVID-19, diabetes, and/or uncontrolled hyperglycemia have significantly higher mortality rates.

The objective of the study was to evaluate the association between birth by cesarean delivery with the offspring's risks of obesity and type 2 diabetes in adulthood.

Individuals with type 1 diabetes, specifically those with poor glycemic control, are at an greater risk for cardiovascular disease than the general population, according to a study by Joslin Research.

Research from Wuhan, China, found that those with diabetes and high blood pressure were overrepresented among severely ill patients and those who have passed away from COVID-19.

In response to the financial crisis driven by the coronavirus disease 2019 (COVID-19) pandemic, drug manufacturers are aiming to increase access to insulin products.

Adult patients with type 2 diabetes requiring insulin therapy can safely achieve good blood sugar control using regular human insulin in a wearable, patch-like insulin delivery device called V-Go.

School closures during the COVID-19 epidemic raises unique challenges regarding the benefits weighed against the costs of resulting health care worker absenteeism.

In addition to differing symptom presentations and health challenges during the COVID-19 pandemic, caretakers and medical professionals should be aware of older adults’ mental and emotional health.

Key best practices for protecting pharmacy personnel during the COVID-19 pandemic.

The waivers were approved within days of the states' submissions.

Curtis E. Haas, PharmD, FCCP, editor-in-chief of Pharmacy Times: Directions in Health-System Pharmacy, and chief pharmacy officer for the University of Rochester’s health care system, discusses preparation for potential patient surge due to COVID-19.

Today’s pharmacy hero is Diane Berkley, CPhT. In addition to working full time at a local hospital during the day, Berkley also works part-time at a community pharmacy.

The FDA has issued a statement regarding action to help increase the supply of ventilators, ventilator tubing connectors, and ventilator accessories during the COVID-19 pandemic.

Top news of the week from Pharmacy Times® surrounding the novel coronavirus.

The FDA has issued a complete response letter for the supplemental New Drug Application of the investigational medicine empagliflozin 2.5 mg as an adjunct to insulin for adults with type 1 diabetes.

The EUA designation allows the test to be used to detect SARS-CoV-2, the virus that causes COVID-19, for the duration of the continuing pandemic.

Here is an overview of reported investigations of existing medications.

Pregabalin capsules is used to treat pain caused by nerve damage due to diabetes or shingles infection.

Hoth Therapeutics and Voltron Therapeutics will collaborate to develop the self-assembling vaccine technology as a means to aid patients at risk of being infected with COVID-19.

Mandatory, scripted patient education and device demonstrations are vital to avoid harm.

The researchers found that the average yearly out-of-pocket spending by patients with diabetes is over $1,800.

The law makes New Mexico the third state to enact a co-pay cap for insulin.

Rotovirus infection is a hypothesized risk factor for type 1 diabetes, according to the authors.

Among insured adults with diabetes in the United States, 40% struggle to pay for care according to a new report.

Online pharmacy Valisure has found high levels of N-Nitrosodimethylamine (NDMA), a probable human carcinogen, in batches of metformin from 11 out of 22 tested manufacturers.1

By changing the definition of biological products and hopefully increasing access to cheaper insulin, the FDA hopes to do just that.

Using metformin for type 1 diabetes and handling eye irritation—how would you respond to these cases?

In order to increase the effectiveness of adherence interventions, we need to take into account the fact that human beings are not always rational.

Researchers perform the most comprehensive evaluation of the cardiovascular risk of type 2 diabetes drug rosignlitazone ever completed.